Mineralocorticoid Receptor in Endothelial Cells Contributes to Vascular Endothelial Growth Factor Receptor Inhibitor-Induced Vascular and Kidney Damage
American Journal of Hypertension · 2025
DOI: 10.1093/ajh/hpae140 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Hypertension, 2025. Verfasst von Nicholas D Camarda und 5 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Cardiology Research Institute, Tufts Medical Center, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Receptors, Mineralocorticoid, Endothelial Cells, Receptors, Vascular Endothelial Growth Factor, Hypertension. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIGMS NIH HHS, NHLBI.
Abstract (Originalsprache)
BACKGROUND Vascular endothelial growth factor receptor inhibitors (VEGFRis) improve cancer patient survival by inhibiting tumor angiogenesis. However, VEGFRis induce treatment-limiting hypertension which has been associated with impaired vascular endothelial cell (EC) function and kidney damage. The mineralocorticoid receptor (MR) regulates blood pressure (BP) via its effects on the vasculature and the kidney. Thus, we interrogated the role of the MR in EC dysfunction, renal impairment, and hypertension in a mouse model of VEGFRi-induced hypertension using sorafenib. METHODS EC dysfunction in mesenteric arterioles was assessed by immunoblotting for phosphorylation of endothelial nitric oxide synthase (eNOS) at serine 1177. Renal damage was measured by assessing glomerular endotheliosis histologically. BP was measured using implanted radiotelemetry. RESULTS Six days of sorafenib treatment significantly impaired mesenteric resistance vessel EC function, induced renal damage, and increased BP. Pharmacologic MR blockade with spironolactone prevented the sorafenib-induced decline in eNOS phosphorylation and renal glomerular endotheliosis, without affecting systolic BP (SBP) or diastolic BP. Mice with the MR knocked out specifically in ECs (EC-MR-KO) were protected from sorafenib-induced EC dysfunction and glomerular endotheliosis, whereas smooth muscle cell-specific MR (SMC-MR) knockout mice were not. Neither EC-MR nor SMC-MR knockout affected the degree to which sorafenib increased SBP or diastolic BP. CONCLUSIONS These results reveal that the MR, specifically in EC but not in SMCs, is necessary for VEGFRi-induced renal and vascular injury. While ineffective at lowering SBP, these data suggest potential therapeutic benefits of MR antagonists, like spironolactone, to protect the vasculature and the kidneys from VEGFRi-induced injury.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Cardiology Research Institute, Tufts Medical Center, Boston, Massachusetts, USA.
- Genetics, Molecular, and Cellular Biology Program, Tufts Graduate School of Biomedical Sciences, Boston, Massachusetts, USA.
ORCID-Profile: Nicholas D Camarda
Förderung
- NHLBI NIH HHS
- NIGMS NIH HHS
- NHLBI
Zitieren
APA
Camarda, N. D., Lu, Q., Tesfu, A. F., Liu, R. R., Ibarrola, J., & Jaffe, I. Z. (2025). Mineralocorticoid Receptor in Endothelial Cells Contributes to Vascular Endothelial Growth Factor Receptor Inhibitor-Induced Vascular and Kidney Damage. American Journal of Hypertension. https://doi.org/10.1093/ajh/hpae140
Vancouver
Camarda ND, Lu Q, Tesfu AF, Liu RR, Ibarrola J, Jaffe IZ. Mineralocorticoid Receptor in Endothelial Cells Contributes to Vascular Endothelial Growth Factor Receptor Inhibitor-Induced Vascular and Kidney Damage. American Journal of Hypertension. 2025. doi:10.1093/ajh/hpae140
BibTeX
@article{Camarda2025,
author = {Camarda, Nicholas D and Lu, Qing and Tesfu, Angelina F and Liu, Rui R and Ibarrola, Jaime and Jaffe, Iris Z},
title = {Mineralocorticoid Receptor in Endothelial Cells Contributes to Vascular Endothelial Growth Factor Receptor Inhibitor-Induced Vascular and Kidney Damage},
journal = {American Journal of Hypertension},
year = {2025},
doi = {10.1093/ajh/hpae140}
}
EUVIMED